460 related articles for article (PubMed ID: 15836660)
21. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
22. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
24. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
25. Alpha-tocopherol supplementation decreases electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis patients.
Mafra D; Santos FR; Lobo JC; de Mattos Grosso D; Barreira AL; Velarde LG; Abdalla DS; Leite M
Nephrol Dial Transplant; 2009 May; 24(5):1587-92. PubMed ID: 19176686
[TBL] [Abstract][Full Text] [Related]
26. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery.
Riahi S; Schmidt EB; Amanavicius N; Karmisholt J; Jensen HS; Christoffersen RP; Niebuhr U; Christensen JH; Toft E
Int J Cardiol; 2006 Aug; 111(3):436-41. PubMed ID: 16290290
[TBL] [Abstract][Full Text] [Related]
27. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Dogra G; Irish A; Chan D; Watts G
Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
[TBL] [Abstract][Full Text] [Related]
29. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
30. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
Schrott HG; Knapp H; Davila M; Shurzinske L; Black D
Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
[TBL] [Abstract][Full Text] [Related]
32. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
33. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
[TBL] [Abstract][Full Text] [Related]
34. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
35. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Wanner C; Krane V
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
[TBL] [Abstract][Full Text] [Related]
36. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
[TBL] [Abstract][Full Text] [Related]
37. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
[TBL] [Abstract][Full Text] [Related]
38. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
[TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Hirsch M; O'donnell J; Olsson A
Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
[TBL] [Abstract][Full Text] [Related]
40. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
Geiss HC; Otto C; Schwandt P; Parhofer KG
Metabolism; 2001 Aug; 50(8):983-8. PubMed ID: 11474489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
